Navigation Links
IncentOne Receives Incentive Platinum Partner Award
Date:10/29/2007

am possible with a proven track record of delivering innovative "Best in Class" incentive solutions.

About IncentOne

IncentOne provides integrated incentive solutions to employers, from small businesses to the FORTUNE(R) 500, including half of the FORTUNE(R) 50. IncentOne's technology solutions provide the tools to drive health care cost reduction and productivity improvement. Read its recent issue brief, The Art and Science of Health Incentives, at http://www.IncentOne.com/IssueBrief. For more information, please visit http://www.IncentOne.com.

About Incentive

Incentive, published by Nielsen Business Media, is the only publication devoted exclusively to motivation and performance improvement through the use of incentive programs and consumer promotions. It is a first-read for executives looking to improve company performance and a first-buy for advertisers looking to reach the most qualified incentive buyer decision-makers. The Incentive advantage is a direct result of more than 100 years of industry experience coupled with the highest subscriber qualification standards in the industry. Incentive helps both advertisers and subscribers reach their goals.


'/>"/>
SOURCE IncentOne
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... details of normal sperm development, demonstrating how chemotherapy or ... pursuing ways to restore fertility have earned a major ... M. D. Anderson Cancer Center. , Marvin Meistrich, Ph.D., ... Oncology, will be inducted as a fellow of the ...
... for Introducing Key Legislation WASHINGTON, Feb. 13 ... applauded the efforts of Senator Jay Rockefeller (D-WV), ... and Representative Bob Filner, Chairman of the House ... amend Section 7422 of Title 38, expanding the ...
... atherosclerosis drug that can reduce the build-up of dangerous ... liver disease (which leads to its own set of ... in mice could lead to a new type of ... of this drug, called DMHCA, are proteins called the ...
... Basic arithmetic and "number sense" appear to be part ... the use of language to explain abstractions that apparently ... , Elizabeth Brannon, an assistant professor of psychology and ... infants, lemurs, and monkeys think about numbers without using ...
... Shield of Michigan supports physical activity and nutrition programs ... than 16,600 Michigan children and their local communities will ... other physical activities and to learn to eat healthily, ... Michigan.They,ll join youngsters like those at Detroit,s Maybury Elementary ...
... Feb. 13 Weight Watchers International, Inc. (NYSE: ... investors and analysts on Thursday, March 5th in New ... provide an overview of the Company,s operations and initiatives.Presentations ... conclude by approximately 12:00 p.m. ET. The event will ...
Cached Medicine News:Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 2Health News:Male fertility expert Marvin Meistrich elected AAAS Fellow 3Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2Health News:Pre-verbal number sense common to monkeys, babies, college kids 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 3Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 4Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 5Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 6Health News:Weight Watchers to Host Investor Meeting 2
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a medical ... products to treat voiding dysfunctions, today reported financial results ... Global revenue for the Company,s Urgent ® ... new quarterly revenue record, as compared to $3.9 million ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... internal candidate to enter Phase 2 clinical development, ... PCOP ), an innovator in the discovery and ... initiation of a Phase 2a,clinical study of PS433540, ... dual-acting angiotensin and endothelin receptor antagonist,(DARA) that is ...
... in Normal Volunteers, BERKELEY HEIGHTS, N.J., Sept. 17 ... Food and Drug Administration (FDA) has,allowed the Investigational New ... its new drug known as G4544. In addition, Genta ... has been treated,with single doses of G4544 without experiencing ...
Cached Medicine Technology:Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 2Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 3Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease 4
... is an immunochromatography based one step ... qualitative determination of Methamphetamine in human ... 1000 ng/mL. This assay has not ... care,location and is for use by ...
... a qualitative immunoassay intended to ... usage of cocaine by detecting ... in human urine at a ... It is for health care,professional ...
... Biosystems introduced the completely automated, 16-capillary ... Genetic Analyzer.,Now the innovative technology of ... our new four-capillary ABI PRISM 3100-Avant ... needs, the fully automated 3100-Avant system ...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Medicine Products: